Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation

IF 0.8 4区医学 Q4 IMMUNOLOGY

Transplantation proceedings Pub Date : 2026-07-01 Epub Date: 2026-06-08 DOI:10.1016/j.transproceed.2026.05.018

Anju Pradeep, Muhammad Saad Faisal, Kelly Chen, Tepe Gokturk, Bradley Karmo, Agustin Gavidia Rosario, Ingrid Rocha, Muhammad Shahzil, Minahil Fatima, Maria Rehmani, Mark Obri, Muhammad Salman Faisal, Syed-Mohammed Jafri

{"title":"Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation","authors":"Anju Pradeep, Muhammad Saad Faisal, Kelly Chen, Tepe Gokturk, Bradley Karmo, Agustin Gavidia Rosario, Ingrid Rocha, Muhammad Shahzil, Minahil Fatima, Maria Rehmani, Mark Obri, Muhammad Salman Faisal, Syed-Mohammed Jafri","doi":"10.1016/j.transproceed.2026.05.018","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Glucagon-Like Peptide-1 (GLP-1) analogues are increasingly being used to manage diabetes and obesity. However, their use in liver transplant (LT) recipients remains understudied. This study aimed to evaluate the clinical outcomes associated with GLP-1 use following LT.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of adult LT recipients between 2019-2023 at a single tertiary care center. Patients were divided into 2 groups based on GLP-1 use after transplant. Baseline demographics, comorbidities, transplant characteristics, and post-transplant outcomes were compared. Categorical variables were analyzed using Chi-square tests, and continuous variables using t-tests.</div></div><div><h3>Results</h3><div>Among 368 LT recipients, 73 (19.8%) were prescribed GLP-1 analogues post-transplant and 295 (80.2%) were not. There was no difference in demographics. GLP-1 users had higher rates of diabetes (79.5% vs. 31.2%, <em>p</em> < .0001), hyperlipidemia (50.7% vs. 29.8%, <em>p</em> = .0012), and BMI at transplant (31.9 ± 6.3 vs. 28.5 ± 12.6, <em>p</em> = .0015). MASH was the leading indication for transplant in the GLP-1 group (61.9% vs. 38.1%, <em>p</em> < .0001). At year 1, GLP-1 users had lower rejection rates (12.3% vs. 23.1%, <em>p</em> = .0635), with a similar trend at 3 years (6.8% vs. 9.5%, <em>p</em> = .6322). At 3 years, mortality was lower in GLP-1 users (1.4% vs. 4.7%, <em>p</em> = .3293).</div></div><div><h3>Discussion</h3><div>GLP-1 analogues were commonly used post-LT in patients with MASH and obesity. Despite higher metabolic burden at baseline, GLP-1 use was associated with similar or improved trends in BMI, rejection, and mortality. Larger prospective studies are needed to strengthen the evidence supporting the use of GLP-1 analogues in this high-risk population.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"58 6","pages":"Pages 1092-1096"},"PeriodicalIF":0.8000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation proceedings","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041134526002757","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Glucagon-Like Peptide-1 (GLP-1) analogues are increasingly being used to manage diabetes and obesity. However, their use in liver transplant (LT) recipients remains understudied. This study aimed to evaluate the clinical outcomes associated with GLP-1 use following LT.

Methods

We conducted a retrospective cohort study of adult LT recipients between 2019-2023 at a single tertiary care center. Patients were divided into 2 groups based on GLP-1 use after transplant. Baseline demographics, comorbidities, transplant characteristics, and post-transplant outcomes were compared. Categorical variables were analyzed using Chi-square tests, and continuous variables using t-tests.

Results

Among 368 LT recipients, 73 (19.8%) were prescribed GLP-1 analogues post-transplant and 295 (80.2%) were not. There was no difference in demographics. GLP-1 users had higher rates of diabetes (79.5% vs. 31.2%, p < .0001), hyperlipidemia (50.7% vs. 29.8%, p = .0012), and BMI at transplant (31.9 ± 6.3 vs. 28.5 ± 12.6, p = .0015). MASH was the leading indication for transplant in the GLP-1 group (61.9% vs. 38.1%, p < .0001). At year 1, GLP-1 users had lower rejection rates (12.3% vs. 23.1%, p = .0635), with a similar trend at 3 years (6.8% vs. 9.5%, p = .6322). At 3 years, mortality was lower in GLP-1 users (1.4% vs. 4.7%, p = .3293).

Discussion

GLP-1 analogues were commonly used post-LT in patients with MASH and obesity. Despite higher metabolic burden at baseline, GLP-1 use was associated with similar or improved trends in BMI, rejection, and mortality. Larger prospective studies are needed to strengthen the evidence supporting the use of GLP-1 analogues in this high-risk population.

查看原文本刊更多论文

胰高血糖素样肽-1激动剂对肝移植术后体重轨迹和临床结果的影响。

胰高血糖素样肽-1 （GLP-1）类似物越来越多地被用于治疗糖尿病和肥胖。然而，它们在肝移植（LT）受者中的应用仍未得到充分研究。本研究旨在评估肝移植后GLP-1使用相关的临床结果。方法：我们对2019-2023年在单个三级医疗中心接受肝移植的成人进行了回顾性队列研究。根据移植后GLP-1的使用情况将患者分为两组。比较基线人口统计学、合并症、移植特征和移植后结果。分类变量采用卡方检验，连续变量采用t检验。结果：在368名肝移植受体中，73名（19.8%）移植后使用GLP-1类似物，295名（80.2%）未使用。人口统计学上没有差异。GLP-1使用者的糖尿病（79.5% vs. 31.2%, p < .0001）、高脂血症（50.7% vs. 29.8%, p = .0012）和移植时BMI（31.9±6.3 vs. 28.5±12.6,p = .0015）的发生率较高。在GLP-1组中，MASH是移植的主要指征（61.9% vs. 38.1%, p < 0.0001）。在第1年，GLP-1使用者的排异率较低（12.3%对23.1%,p = .0635）， 3年的趋势相似（6.8%对9.5%,p = .6322）。3年时，GLP-1使用者的死亡率较低（1.4% vs. 4.7%, p = .3293）。讨论：GLP-1类似物常用于糖尿病合并肥胖患者的肝移植后。尽管在基线时代谢负担较高，但GLP-1的使用与BMI、排斥反应和死亡率的相似或改善趋势相关。需要更大规模的前瞻性研究来加强支持在高危人群中使用GLP-1类似物的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation proceedings 医学-免疫学

CiteScore

1.70

自引率

0.00%

发文量

502

审稿时长

60 days

期刊介绍： Transplantation Proceedings publishes several different categories of manuscripts, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. The first type of manuscripts consists of sets of papers providing an in-depth expression of the current state of the art in various rapidly developing components of world transplantation biology and medicine. These manuscripts emanate from congresses of the affiliated transplantation societies, from Symposia sponsored by the Societies, as well as special Conferences and Workshops covering related topics. Transplantation Proceedings also publishes several special sections including publication of Clinical Transplantation Proceedings, being rapid original contributions of preclinical and clinical experiences. These manuscripts undergo review by members of the Editorial Board. Original basic or clinical science articles, clinical trials and case studies can be submitted to the journal?s open access companion title Transplantation Reports.